ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 803

Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment

Kenan Barut 1, Amra Adrovic 2, Sezgin Sahin 3, Mehmet Yıldız 2, Oya Koker 2, Gamze Yalcin 2, Omer Faruk Beser 4, Bekir Kocazeybek 5, Pelin Yuksel 5 and Ozgur Kasapcopur6, 1Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, İstanbul, Istanbul, Turkey, 2Department of Pediatric Rheumatology, Istanbul University Cerrahpasa, Istanbul, Istanbul, Turkey, 3Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Istanbul, Turkey, 4Department of Pediatrics, Okmeydani Education and Training Hospital, Istanbul, Istanbul, Turkey, 5Department of Microbiology, Istanbul University Cerrahpasa, Istanbul, Istanbul, Turkey, 6Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Autoinflammatory diseases, canakinumab and tocilizumab, Hepatitis A, Vaccination

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 10, 2019

Session Title: Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Autoimmune, autoinflammatory mechanism and drugs used in treatment increase the risk of liver disease in patients with chronic rheumatic diseases. Hepatitis A vaccine is a highly effective vaccine that prevents both the formation and spread of clinical hepatitis. In childhood chronic rheumatic diseases, vaccination is of great importance. The risk of various infections increases with the immunosuppressive effect of both the disease and the drugs.Therefore, vaccination of these diseases is of high importance for the prevention of infectious diseases. Studies on the efficacy and safety of vaccines in autoimmune and autoinflammatory diseases are limited. The aim of this study was to investigate the efficacy and safety of hepatitis A vaccine in patients with autoinflammatory disease on anti-interleukin 1 and 6 treatment.

Methods: This study was carried out in Pediatric Rheumatology outpatient clinic and general paediatric outpatient clinic. A total of 39 patients with autoinflammatory diseases on anti IL-1 and IL-6 therapy were initially evaluated but 25 of them were excluded due to anti-HAV IgG positivity. At the end, 24 patients with  autoinflammatory diseases on anti IL-1, anti IL-6 therapy  and 39 healthy participants who were seronegative for hepatitis A received two doses of the hepatitis A vaccine in a 0 and 6 month schedule. Hepatitis A virus (HAV) IgG antibodies were measured before vaccination and one month after last dose of the vaccine. Anti-HAV IgG titer as S/ CO;1.1, IU/L was considered positive and protective.

Results: Total 24 patients with autoinflammatory condition and 39 healthy controls  were included in the study.  Among patients with diagnosis of autoinflammatory disease, 19 were Systemic juvenile idiopathic arthritis (SJİA) and 5 were Cryopyrin-associated periodic syndromes (CAPS) patients. The mean age was 14.1±3.7 and 12.2±3.3 years respectively. Canakinumab was used in 15 (62.5%) and tocilizumab in 9 (37.5%) all patients. Among all SJİA patients, 10 (52.6%) were treated with canakinumab and 9(47.4%) were treated with tocilizumab. All patients with CAPS (n: 5) were using canakinumab. Among SJIA cases, 15(75%) were also using methotrexate and 14(70%) prednisolone.  Anti-HAV IgG concentrations were measured one month after the last dose of hepatitis A vaccine. There was statistically significant difference between patients with autoinflammatory condition and healthy controls regarding the anti-HAV IgG titer (mean 5.3±1.5 IU/L) versus (10.5±7 IU/L) p< 0.05. The rate of anti-HAV IgG seropositivity (cut-off 1.1 IU/L) in autoinflammatory disease (24/24 (100%) was significantly different comparing to healthy controls (33/39, 84.6%) (p=0.04). There was no disease flare of disease nor the adverse event detected in any patients after vaccination. Conclusion: Anti-HAV IgG seroconversion was detected in patients with autoinflammatory disease on anti-IL1 and anti – IL6 therapy 1 month after the last dose of hepatitis A vaccine. The response to vaccine did not differ between healthy children and patients with autoinflammatory disease under canakinumab and tocilizumab. In this study hepatitis A vaccine was found to be safe in autoinflammatory diseases with canakinumab and tocilizumab treatment.


Disclosure: K. Barut, AbbVie, 2; A. Adrovic, None; S. Sahin, AbbVie, 2; M. Yıldız, None; O. Koker, None; G. Yalcin, None; O. Beser, None; B. Kocazeybek, None; P. Yuksel, None; O. Kasapcopur, AbbVie, 2.

To cite this abstract in AMA style:

Barut K, Adrovic A, Sahin S, Yıldız M, Koker O, Yalcin G, Beser O, Kocazeybek B, Yuksel P, Kasapcopur O. Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/hepatitis-a-virus-vaccination-in-autoinflammatory-diseases-under-canakinumab-and-tocilizumab-treatment/. Accessed January 16, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hepatitis-a-virus-vaccination-in-autoinflammatory-diseases-under-canakinumab-and-tocilizumab-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.